Department of Hematology: Erythrocytes

Patient Name : Mr.
AMIT KUMAR BAGCHI Barcode NO : 10378273

Age/Gender : 42 Y/Male Registration ON : 04/Sep/2021
LabNo : 012109040899 Sample Collected ON : 04/Sep/2021
Referred By :Dr. PRE EMPLOYMENT MEDICAL Sample Received ON : 04/Sep/2021
Client Code :WBCL/NAPH/RK Report Generated ON : 04/Sep/2021 08:18PM
Refer Lab/Hosp : Sample Status : Final Approved
DEPARTMENT OF HEMATOLOGY
Test Name Value Unit Bio Ref.Interval
CBC*
Erythrocytes
Haemoglobin* 13.2 g/dL 13-17
(Method:Spectrophotometry) (Sample:EDTA )
RBC Count* 4.6 10^12/L 4.5-5.5
(Method:Cell Impedance) (Sample:EDTA )
PCV (Packed Cell Volume)* 43.2 % 40-50
(Method:Calculated ) (Sample:EDTA )
MCV (Mean Corpuscular Volume)* 93.9 fl 81-101
(Method:Calculated) (Sample:EDTA )
MCH (Mean Corpuscular Hemoglobin)* 28.7 pg 27-32
MCHC (Mean Corpuscular Hemoglobin 30.6 g/dL 32.5-34.5
Concentration)*
RDW-CV* 12.9 % 11.6-14.0
Leucocytes
WBC Count,Total* 5,200 Cells/µL 4,000-11,000
Differential Leucocyte Count
Neutrophils* 58 % 40-70
Lymphocytes* 35 % 20-40
Eosinophils* 4 % 1-6
Monocytes* 3 % 2-10
Basophils* 0 % 0-2
Absolute Neutrophil Count* 3,016 Cells/µL 2000-7000
Absolute Lymphocyte Count* 1,820 Cells/µL 1000-3000
Absolute Eosinophil Count* 208 cells/µL 20-500
Absolute Monocyte Count* 156 Cells/µL 20 - 500
Page 1 of 13
Patient Name : Mr.AMIT KUMAR BAGCHI Barcode NO : 10378273
Absolute Basophil Count* 0 Cells/µL <200

Thrombocytes
Platelet Count* 186 10^9/L 150-410
(Method:Cell Impedance ) (Sample:EDTA )
Erythrocyte Sedimentation Rate
ESR* 12 mm in 1hr 10 or less
(Method:Westergren method) (Sample:EDTA )
Morphology
RBC Morphology* Normocytic and Normochromic.
(Method:Microscopic) (Sample:EDTA )
WBC Morphology* No abnormal cell seen.
(Method:Microscopic) (Sample:EDTA )
Platelets* Adequate.
(Method:Microscopy) (Sample:EDTA )
Note:
As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per
unit volume of blood.
Page 2 of 13
Blood Grouping (ABO)* A -

(Method:Tube Agglutination) (Sample:EDTA)
Rh Typing* Positive -
(Method:Tube Agglutination) (Sample:EDTA)
Page 3 of 13
DEPARTMENT OF BIOCHEMISTRY
Nirnay 61.1 - LFT Panel With GGT
Glucose - Fasting 85 mg/dL Normal tolerance: 70 - 110

(Method:GOD-POD) (Sample:Fluoride Plasma) Pre-Hyperglycemia: 111 - 125
Hyperglycemia: ≥ 126
Comments:
1. Glucose is a reducing monosaccharide seves as the principal fuel for all tissues.It enters the cell through influence of insulin and undergoes a series of chemical reactions to produce energy.
2. Lack of insulin or resistance to its action at the cellular level causes diabetes.Therefore,in diabetes mellitus the blood glucose levels are very high. Hyperglycemia is also noted in gestational
diabetes of pregnancy and may be found in pancreatic disease,pituitary and adrenal disorders.A decreased level of blood glucose, hypoglycemia is often associated with starvation,hyper
insulinemia and in those who are taking high insulin dose for therapy.
3. Clinical diagnosis should not be made on the findings of a single test result,but should integrate both clinical and laboratory data.
Note: For pre-hyperglycemic results please repeat the test with fresh samples for 2 consecutive days is recommended.
Reference: www.who.int/diabetes/publications/
Glucose - Post Prandial(PP) 104 mg/dL Normal tolerance: 70 - 140

(Method:GOD-POD) (Sample:Fluoride Plasma) Pre-Hyperglycemia: 141 - 199
Hyperglycemia: ≥ 200
Comment:
The postprandial glucose blood sugar test is primarily used to test for and diagnose Type 1, Type 2, and gestational diabetes. The test is also used to detect complications of diabetes and to track
the results of diabetes treatment. The test measures the level of glucose in the blood.
Note: For pre-hyperglycemic results please repeat the test with fresh samples for 2 consecutive days is recommended.
Reference: www.who.int/diabetes/publications/
Urea 17.0 mg/dL 10 - 50

(Method:Urease - GLDH) (Sample:Serum)
Comments:
1. Urea is synthesized in liver as a by-product of deamination of aminoacids.

2. Urea is measured to monitor patients undergoing dialysis and evaluate renal and metabolic function.
3. Higher than normal levels of urea indicate problems with kidney function however levels are increased as a result of congestive heart failiour, heart attack, shock and dehydration.
4. Lower than normal levels are not usually of clinical significance however have been associated with pregnency and liver disease.
Page 4 of 13
Creatinine 0.92 mg/dl 0.7-1.4

(Method:MODIFIED JAFFE) (Sample:Serum)
Comments:
Creatinine is a catabolic end product of creatine. The amount produced each day is related to the muscle mass. Creatinine is freely filtered by glomerulus,(small amounts are reabsorbed and
secreted by renal tubules). Creatinine is measured for the assessment of kidney function(impaired renal perfusion, loss of functioning nephrons) and in monitoring renal dialysis. The method
commonly used for estimating Creatinine makes use of Jaffe’ reaction with an alkaline picrate reagent.
Uric Acid 4.2 mg/dL 2.5 - 7.0

(Method:Uricase - POD) (Sample:Serum)
Comments:
1. Uric acid is a major product of catabolism of perine bases, obtained partly from diet and party from in vivo synthesis.
2. Increased Uric acid concentration in serum, Hyperrucicemia is commonly associated with gout, decreased renalfunction, dehydration,myeloproliferative disorders.
3. Hypouricemia may be due to fanconi syndrome, Wilson's deases, Diabetes mellitus, Low purine diet.
4. Uric acid in serum is estimated by Henry-caraway's method and enzymatic method.
Bilirubin Total 0.59 mg/dL < 1.0

(Method:DSA) (Sample:Serum)
Bilurubin Direct 0.18 mg/dL 0.0-0.3
(Method:DSA) (Sample:Serum)
Bilurubin Indirect 0.41 mg/dL 0.2 - 1.0
(Method:Calculated) (Sample:Serum)
Comments:
1. Bilirubin is a waste product derived from the heme moeity of the heamoglobin released from senescent or damaged erythrocytes.
2. Total bilirubin is the sum of the unconjugated and conjugated fractions.
3. Total bilirubin is elevated in conditions causing obstration of the bill duct, hepatitis(jaundice), cirrohosis, in haemolytic disorders and ceveral inherited enzyme deficiencies. Indirect bilirubin
is elevated by prehepatic causes such as haemolyitc disorders or liver diseases resulting in inpaired entry, tranport or conjugation within the liver.
4. Monitoring of bilirubin in the new born, particularly if pre mature is off particular importance. Unconjugated bilirubin if not bound to albumin is able to cross the blood brain barrier more
easily, increasing the danger of cerebral damage.
Page 5 of 13
AST/SGOT 23 U/L ≤ 37

(Method:IFCC without P5P) (Sample:Serum)
Comments:
1. AST is found in highest concentration in the liver and heart muscle, also abudant in skeletal muscle, kidney & pancreas.
2. High levels of AST seen in severe liver disease, myocardial infraction, heart attack or heart failure, hepatitis, cholestasis cirrhosis and after administration of various drugs.
ALT/SGPT 31 U/L ≤ 40

(Method:IFCC without P5P) (Sample:Serum)
Comments:
1. ALT is found in plasma and in various bodily tissues, but is most commonly associated with the liver. It is commonly measured clinically as a part of a diagnostic evaluation of hepatocellular
injury, to determine liver health.
2. Significantly elevated levels of ALT (SGPT) often suggest the existence complications such as viral hepatitis, diabetes, congestive heart failure, liver damage, bile duct problems, myopathy.
Alkaline Phosphotase (ALP) 126 U/L 53-128

(Method:IFCC ) (Sample:Serum)
Comments:
1. Alkaline phosphatase catalyzes the hydrolysis of organic monoesters at alkaline pH. Present in all body tissues,cell membranes.
2. High concentrations seen in Placenta,intestinal epithelium,osteoblasts. Elevated in Bone diseases,hepatobiliary disease,liver cancer,hepatotoxicity caused by drugs.
3. Physiological changes, such as bone growth and pregnancy,may cause increases in ALP levels.
Total Protein 7.6 g/dL 6.6 - 8.7

(Method:Biuret) (Sample:Serum)
Albumin 4.5 g/dl 3.5 - 5.3
(Method:BCG) (Sample:Serum)
Globulin 3.1 g/dl 2.0 - 3.5
Albumin / Globulin Ratio 1.4 - 1.0 - 2.1
Comments:
Page 6 of 13
1. Most of the plasma proteins are synthesized by liver. A deviation of serum total protien from reference interval indicates presence of dysprotienemia or disorder in water balance.
2. Hypoproteinemia can caused by liver disorder, kidney disorder, hemodilution, malabsorpitve disease and severe malnutrition.
3. Hyperproteinemia seen with chronic inflammation, dehydration and in multiple myeloma.
Page 7 of 13
Lipid Profile Basic

Cholesterol Total 180 mg/dL Desirable level : < 200
(Method:CHOD PAP) (Sample:Serum) Borderline high : 200-239
High cholesterol : > 240
Cholesterol HDL 45 mg/dL 30 - 70
(Method:Polymer Detergent) (Sample:Serum)
Cholesterol VLDL 44 mg/dL 7 - 40
Cholesterol LDL 91 mg/dL Optimal : < 100
(Method:Polymer Detergent) (Sample:Serum) Near optimal : 100-129
Borderline High : 130-159
High : 160-189
Very high : >= 190
Triglycerides 221 mg/dL Normal : <150
(Method:Glycerol Phosphate Oxidase) (Sample:Serum) Borderline High : 150–199
High : 200–499
Very High : >500
Cholesterol Total / HDL Ratio 4.0 0 - 4.0
Cholesterol LDL / HDL Ratio 2.0 0 - 3.5
Note:
1. Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL
Cholesterol.
2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature
cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
3. Low HDL levels are associated with increased risk forAtherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport,
the process by which cholesterol is eliminated from peripheral tissues.
4. NLA-2014identifies Non HDL Cholesterol(an indicator of all atherogeniclipoproteins such as LDL , VLDL, IDL, Lpa, Chylomicron remnants)along with LDL-cholesterol as co- primary target for
cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.
5. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved.
6. Additional testing for Apolipoprotein B, hsCRP,Lp(a ) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement.
7. For calculation of CHD risk, history of smoking, any medication for hypertension & current blood pressure levels are required.
Page 8 of 13
Gamma Glutamyl Transferase (GGT)* 16.2 U/L 9 - 60

Comments:
1. ˠ‑ Glutamate transaminase (GGT) is a membrane localized enzyme that catalyzes the transfer of glutamyl groups from glutathione to amino acids or peptides.
2. Large GGT amounts are present in secretory organs: kidney, liver, bile duct, pancreas. Although the GGT activity is highest in renal tissue, serum GGT is generally elevated as a result of liver
disease.
3. Since alcohol induces GGT production, measurement of GGT activity is used for monitoring of abstinence in withdrawal treatment.
Page 9 of 13
DEPARTMENT OF IMMUNOLOGY
HIV 1 & 2 Antibody* 0.046 OD < 0.35 : Non Reactive

(Method:ELISA) (Sample:Serum) > 0.35 : Reactive
Interpretation* Non Reactive
Comment:
This tests the presence of antibodies to HIV-I and HIV-II in serum and plasma. The production of antibodies as an immune response against HIV takes about 3-12 weeks (sero-positive). The gap
between infection and sero-positive is the window period. During this period ELISA tests will be negative. The window period usually does not exceed 3months. The ELISA antibody tests have a
sensitivity of about 99%.
False Positive Reaction:
High levels of IgM antibodies.

Anti HLA-ABC and DR antibodies.
Attack of Flu.
Hepatitis ‘B’ vaccinations.
Repeated freezing and thawing of the samples.
Multigravida women.
Presence of Rheumatoid factor.
Alcoholism.
Malignancy.
False Negative Reaction:
Window Period.
Advanced AIDS disease-diminished antibody Titre.
Note: All reactive result is recommended to be confirmed by Western Blot method.
Page 10 of 13
DEPARTMENT OF CLINICAL PATHOLOGY
RE - Stool*
PHYSICAL EXAMINATION
Colour* Deep Brownish -
Consistency* Semi solid -
Mucus* Present -
Blood* Absent
(Method:Reagent Strip Reflectance) (Sample:Stool)
CHEMICAL EXAMINATION
pH* 6.5
(Method:Reagent Strip Reflectance) (Sample:Stool)
MICROSCOPIC EXAMINATION
Pus cells* 01-02 /hpf
(Method:Microscopic) (Sample:Stool)
RBC* Absent /hpf
(Method:Microscopic) (Sample:Stool)
Vegetable Cell* Present
Ova/Eggs* Negative -
Parasite* Negative -
Cyst* Negative -
Others* Nil -
Page 11 of 13
RE - Urine*
PHYSICAL EXAMINATION
Volume* 40 ml
Colour* Pale Yellow
(Method:Visual Examination) (Sample:Random Urine)
Appearence* Slightly Hazy
Sediments* Present
Specific gravity* 1.025
(Method:Reagent Strip Reflectance) (Sample:Random Urine)
CHEMICAL EXAMINATION
pH* 6.2
Protein* Absent
Sugar* Present(+)
(Method:Benedict) (Sample:Random Urine)
Blood* Absent
MICROSCOPIC EXAMINATION
Pus cells* 02-04 /hpf
(Method:Microscopic) (Sample:Random Urine)
Epithelial cells* 01-02 /hpf
RBC* Absent /hpf
Cast* Absent
Crystal* Negative
Micro Organism* Present(few)
Yeast cell* Absent
Test Marked with( * )is not Under Nabl Scope
*** End Of Report ***

1.Partial reproduction of this report is not permitted. 2. If the result(s) of the test(s) is alarming or unexpected, the patient is advised to contact the laboratory immediately for possible advice. 3.Result(s) pertain
Page 12 of 13
to the specimen submitted. 4. Laboratory investigations should be used along with relevant clinical examinations to achieve the final diagnosis. These are never conclusive and dependent on the quality of the
samples as well as the assay procedures used. 5. Test(s) requested might not be performed for the following reasons: (a) Quantity of the specimen received is unacceptable (b)Quality of the specimen received is of
unacceptable quality (hemolyzed/Clotted/Lipemic). In any of these cases, a fresh specimen must be sent for reporting of the same parameters within the schedule (next 2 days). 6. Test(s) are performed as per the test
schedule of the laboratory. In unforeseen circumstances (non availability of reagents, instrument breakdown, and natural calamities) test(s) may not be reported as per test schedule.Nirnayan will ensure that the
delay is minimized.
Page 13 of 13

Department of Hematology: Erythrocytes

Uploaded by

Copyright:

Available Formats

Department of Hematology: Erythrocytes

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Department of Hematology: Erythrocytes

Uploaded by

Copyright:

Available Formats

Patient Name : Mr.

AMIT KUMAR BAGCHI Barcode NO : 10378273

Test Name Value Unit Bio Ref.Interval

Test Name Value Unit Bio Ref.Interval

Absolute Basophil Count* 0 Cells/µL <200

Test Name Value Unit Bio Ref.Interval

Blood Grouping (ABO)* A -

Test Name Value Unit Bio Ref.Interval

Glucose - Fasting 85 mg/dL Normal tolerance: 70 - 110

Glucose - Post Prandial(PP) 104 mg/dL Normal tolerance: 70 - 140

Urea 17.0 mg/dL 10 - 50

1. Urea is synthesized in liver as a by-product of deamination of aminoacids.

Test Name Value Unit Bio Ref.Interval

Creatinine 0.92 mg/dl 0.7-1.4

Uric Acid 4.2 mg/dL 2.5 - 7.0

Bilirubin Total 0.59 mg/dL < 1.0

Test Name Value Unit Bio Ref.Interval

AST/SGOT 23 U/L ≤ 37

ALT/SGPT 31 U/L ≤ 40

Alkaline Phosphotase (ALP) 126 U/L 53-128

Total Protein 7.6 g/dL 6.6 - 8.7

Test Name Value Unit Bio Ref.Interval

Test Name Value Unit Bio Ref.Interval

Lipid Profile Basic

Test Name Value Unit Bio Ref.Interval

Gamma Glutamyl Transferase (GGT)* 16.2 U/L 9 - 60

Test Name Value Unit Bio Ref.Interval

HIV 1 & 2 Antibody* 0.046 OD < 0.35 : Non Reactive

False Positive Reaction:

High levels of IgM antibodies.

False Negative Reaction:

Note: All reactive result is recommended to be confirmed by Western Blot method.

DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Value Unit Bio Ref.Interval

DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Value Unit Bio Ref.Interval

Test Marked with( * )is not Under Nabl Scope

*** End Of Report ***

DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Value Unit Bio Ref.Interval

You might also like

* End Of Report *